Origin Pharmaceuticals

Origin Biosciences, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on developing and commercializing life-saving treatments for rare genetic diseases. The company's primary achievement is the development of Nulibry (fosdenopterin), which in 2021 became the first therapy approved by the FDA to reduce the risk of mortality in patients with Molybdenum Cofactor Deficiency (MoCD) Type A. Origin Biosciences specializes in addressing ultra-rare metabolic disorders where high unmet medical needs exist. While the commercial rights to Nulibry were subsequently sold to Sentynl Therapeutics, Origin remains a key entity within the BridgeBio portfolio dedicated to rare disease innovation.